08 February 2024
08 February 2024
The trial of JNJ-2113 met both its primary and secondary efficacy endpoints.
The company announced the discontinuation of a Phase III trial of magrolimab.
The AI-powered diagnostic platform can diagnose the presence of aneurysms by analysing computed tomography (CT) scans.
The Phase I/Ib trial aims to assess the safety of a single intravesical dose of ZH9 in on-muscle invasive bladder cancer (NMIBC) patients.
The placebo-controlled trial aims to evaluate the safety and optimal dosage of ZMA001 to treat pulmonary arterial hypertension (PAH).
Drawing from three major hospitals based in China, several authors trained 20 AI predictive models using 6,778,762 laboratory results screening for ovarian cancer.
The BLADE-VG2 and BLADE-OPU2 trials will investigate STIMULAN VG for patients with diabetic foot osteomyelitis and stage IV pressure ulcers.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
